

ANNUAL DECLARATION OF INTERESTS (ADoI)

(Please note that high quality of scientific expertise is by nature based on prior experience and that therefore having an interest does not necessarily mean having a conflict of interest)

Name: FOWLER, Paul

Title: Prof.

Profession: Professor

Current EFSA involvements: Member-FAF Panel 2018-2024 (FAF), Member-WG on Flavourings (FAF), Hearing Expert-WG on Guidance Update on Flavourings (FAF)

Nature of Activities	Period	Organisation	Subject matter
I. Financial investments			NO INTEREST
II. Managerial role	03/2019 - 06/2019	-Name: University of Aberdeen, UNITED KINGDOM, Aberdeen	Interim Head of School, School of Medicine, Medical Sciences & Nutrition. Impact was 4 months with a £7,500 salary uplift = £2,500 before tax etc. Impact on annual earnings: >0% and <5%
III. Member of a scientific advisory entity	01/2017 - 07/2019	-Name: ARN, Agence Nationale de la Recherche, ANR, FRANCE, Paris	Member of CE14 Physiology/Pathophysiology Evaluation Panel <1% of time, evaluating grant applications and attending two 2-day meetings in Paris each year. This role is on an annual basis by invitation Impact on annual earnings: >0% and <5%
IV. Employment	11/2015 - now	-Name: University of Aberdeen, UNITED KINGDOM, Aberdeen	Director of the Institute of Medical Sciences. A 5 year appointment, without separate payment, in addition to my main employment, by the same organisation, listed above. Impact on annual earnings: 0%

	02/1986 - now	-Name: University of Aberdeen, Scottish Funding Council	For the last 5 years my research has focused on the effects of environmental and recreational chemicals on fetal development, health and reproductive function in humans and animals species, predominantly sheep and mice. Current post: August 2008 – Tenured Professor (Chair in Translational Medical Sciences), Division Applied Medicine, University of Aberdeen. SFC-funded, termination date 30.09.2024. My research has NOT specifically included studies of BPA by my own group. Impact on annual earnings: >25%
V. Occasional consultancy	11/2014 - 12/2014	-Name: Agence d'Evaluation de la Recherche et de l'Enseignement Supérieur (AERES), FRANCE	Assessment of research institutes and universities, confidential. Appointments are ad hoc, this is my second since 2013. Impact on annual earnings: >0% and <5%
VI. Research funding	01/2019 - 12/2024	-Name: EC, European Commission H2020	Research project: Female Reproductive toxicity of Endocrine disrupting chemicals (EDCs): a human evidence-based screening and Identification Approach (FREIA) €6,107,832
	10/2017 - 09/2021	-Name: EASTBIO PhD studentship (BBSRC)	Mechanisms via which the human fetus is at risk from over-the-counter analgesics
	01/2017 - 12/2020	-Name: EC, European Commission	Horizon 2020, MSCA-ITN-ETN: "PROTECTiON against Endocrine Disruptors; detection, mixtures, health effects, risk assessment and communication" €3,974,595
	06/2017 - 05/2020	-Name: Medical Research Council	Sex-specific disease aetiology from developmental steroid insults: mechanistic understanding and
	04/2019 - 04/2020	-Name: NHS Grampian Endowments	Research project: Mining the placental proteome for biomarkers of adverse effects of maternal lifestyle: smoking and obesity. £11,700
	09/2016 - 09/2019	-Name: Yorkhill Children's Charity	Maternal smoking, drinking and deprivation: when and how of placental damage. 36 months, GBP 59,988
	06/2017 - 05/2019	-Name: NHS Grampian Endowments	Pathways to breast cancer
	04/2017 - 04/2018	-Name: NHS Grampian Endowments	Modelling the gateways to the human fetus by high-throughput placental molecular transporter protein measurements.
	03/2014 - 10/2017	-Name: Medical Research Council	The human fetal liver: development and response to maternal drug use.
	10/2015 - 09/2017	-Name: University of Aberdeen Development Trust	Maternal smoking, drinking and deprivation: when and how of placental damage.
	09/2016 - 05/2017	-Name: Children's Liver Disease Foundation	Global effects of maternal smoking on the human fetal liver protein profile. 6 months, GBP 4,930
	11/2015 - 10/2016	-Name: The Royal Society, UK	Biomonitoring and effect biomarkers of fetal exposure to bisphenol A.
	10/2013 - 09/2016	-Name: Wellcome TRust	Prenatal programming of adult disease by maternal smoking: the adrenal gland as a key player?
	07/2015 - 06/2016	-Name: NHS Grampian Endowments	Placental molecular transporters in early human pregnancy: identifying open gates to the fetus
	04/2015 - 03/2016	-Name: Society for Endocrinology	The impact of maternal smoking to the human fetal adrenal proteome.
	01/2014 - 12/2015	-Name: Society for Reproduction & Fertility	Does exposure to a complex cocktail of environmental chemicals during pregnancy and lactation alter metabolic and steroid hormone systems in the adult liver?
VII. Intellectual property rights			NO INTEREST

VIII. Other memberships or affiliations	07/2016 - 04/2020	-Name: Glasgow Children's Hospital Charity	Member of the Research Fund Steering Committee UNPAID Impact on annual earnings: 0%
	07/2009 - 07/2015	-Name: Society for Reproduction & Fertility	This is a research charity and was the chair of the council of management 2009-2013. Any small projects funded by this charity, which may have included BPA, are decided by a committee that is independent of me and I have played no role in any such project involving BPA. I then served on the Programme Committee UNPAID Impact on annual earnings: 0%
IX. Other relevant interest	11/2014 - now	-Name: Molecular & Cellular Endocrinology	I am a member of this Editorial Board UNPAID Impact on annual earnings: 0%
	04/2014 - now	-Name: European Commission Research Executive Agency	Expert evaluator of applications for Horizon 2020. At present I have NOT been asked to evaluate any applications and this is likely in part because I am a partner in 3 applications currently being considered by Horizon 2020. These are as follows: Partner in two Horizon 2020 research grant applications currently under consideration: 1. Placental "omics" Diagnostic tools for exposure and disease prevention (PLACENTOMICS), €6 million. 7 partners (Finland, Czech, Spain, Belgium (x2), Austria, UK). Aberdeen share €1million. 2. Innovation in Predictive Risk Assessment of Complex Mixtures of Mycotoxins and Persistent Organic Pollutants (PREDICTMIX), €8 million. 7 partners (Norway (x3), France, UK (x2), Germany). Aberdeen share €1million. Work-package leader in one Horizon 2020 MSCA ITN: 1. Endocrine disruptors; detection, mixtures, health effects, risk assessment and education (PROTECTEd), 8 academic/research institute partners (UK (x2), Norway (x3), Belgium, France, Chile) and 3 SMEs (UK, Netherlands, Belgium). Project designed for 15 ESRs. Impact on annual earnings: 0%
	01/2014 - now	-Name: ELSEVIER	editorial board member for the journal "Molecular & cellular Endocrinology" UNPAID Impact on annual earnings: 0%
	03/2019 - 02/2021	-Name: Molecular Human Reproduction	Editorial Board Impact on annual earnings: 0%
	09/2017 - 03/2018	-Name: Springer Nature, MacMillan Publishers	editorial board of the journal Scientific Reports UNPAID Impact on annual earnings: 0%
	08/2017 - 03/2018	-Name: Scientific Reports	member of the Editorial Board of the journal Scientific Reports UNPAID Impact on annual earnings: 0%

	01/2014 - 12/2017	-Name: Endocrinology	I am a member of the editorial board of the journal "Endocrinology" UNPAID Impact on annual earnings: 0%
	01/2014 - 12/2017	-Name: Endocrine Society	editorial board member for the journal "Endocrinology" UNPAID Impact on annual earnings: 0%
	03/2014 - 09/2016	-Name: Endocrine Society	Economic costs of endocrine disrupting chemicals UNPAID Impact on annual earnings: 0%
	03/2014 - 02/2016	-Name: European Commission COST	Targeted Network Rapporteur. This is for "Gender, Science, Technology and Environment - genderSTE". Targeted Networks are policy-driven initiatives approved by the CSO under the COST Plan for Strategic Activities. My duties are to assess progress made by the project and whether it should be extended further. Impact on annual earnings: >0% and <5%
X. Interests of close family members			NO INTEREST

I hereby declare that I have read both the Guidance Document on Declarations of Interests and the Procedure for identifying and handling potential conflict of interests and that the above Declaration of Interests is complete.

Date: 25/05/2020 Signature: **SIGNED**